AEZS Stock Summary and Trading Ideas (Aeterna Zentaris | NASDAQ:AEZS)

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.

Aeterna Zentaris trades on the NASDAQ stock market under the symbol AEZS.

As of September 25, 2023, AEZS stock price declined to $2.49 with 3,187 million shares trading.

AEZS has a market cap of $12.09 million. This is considered a Sub-Micro Cap stock.

Last quarter Aeterna Zentaris reported $2 million in Revenue and -$.52 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.35.

In the last 3 years, AEZS stock traded as high as $90.50 and as low as $2.32.

AEZS has underperformed the market in the last year with a return of -39.6%, while the SPY ETF gained +17.2%. In the last 3 month period, AEZS fell short of the market, returning -7.4%, while SPY returned -0.6%. However, in the most recent 2 weeks AEZS has outperformed the stock market by returning +0.4%, while SPY returned -2.6%.

AEZS support price is $2.37 and resistance is $2.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AEZS stock will trade within this expected range on the day.